van Gisbergen Marike W, Zwilling Emma, Dubois Ludwig J
The M-Lab, Department of Precision Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands.
Department of Dermatology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, Netherlands.
Front Oncol. 2021 May 10;11:653621. doi: 10.3389/fonc.2021.653621. eCollection 2021.
To meet the anabolic demands of the proliferative potential of tumor cells, malignant cells tend to rewire their metabolic pathways. Although different types of malignant cells share this phenomenon, there is a large intracellular variability how these metabolic patterns are altered. Fortunately, differences in metabolic patterns between normal tissue and malignant cells can be exploited to increase the therapeutic ratio. Modulation of cellular metabolism to improve treatment outcome is an emerging field proposing a variety of promising strategies in primary tumor and metastatic lesion treatment. These strategies, capable of either sensitizing or protecting tissues, target either tumor or normal tissue and are often focused on modulating of tissue oxygenation, hypoxia-inducible factor (HIF) stabilization, glucose metabolism, mitochondrial function and the redox balance. Several compounds or therapies are still in under (pre-)clinical development, while others are already used in clinical practice. Here, we describe different strategies from bench to bedside to optimize the therapeutic ratio through modulation of the cellular metabolism. This review gives an overview of the current state on development and the mechanism of action of modulators affecting cellular metabolism with the aim to improve the radiotherapy response on tumors or to protect the normal tissue and therefore contribute to an improved therapeutic ratio.
为满足肿瘤细胞增殖潜能的合成代谢需求,恶性细胞倾向于重新调整其代谢途径。尽管不同类型的恶性细胞都存在这种现象,但这些代谢模式如何改变在细胞内存在很大差异。幸运的是,正常组织与恶性细胞之间代谢模式的差异可被利用来提高治疗比率。调节细胞代谢以改善治疗结果是一个新兴领域,在原发性肿瘤和转移性病变的治疗中提出了多种有前景的策略。这些策略能够使组织敏感化或起到保护作用,靶向肿瘤组织或正常组织,并且通常集中于调节组织氧合、缺氧诱导因子(HIF)稳定、葡萄糖代谢、线粒体功能和氧化还原平衡。一些化合物或疗法仍处于(临床前)临床开发阶段,而其他一些已经在临床实践中使用。在此,我们描述从实验台到病床的不同策略,以通过调节细胞代谢来优化治疗比率。本综述概述了影响细胞代谢的调节剂的当前开发状态及其作用机制,旨在改善肿瘤的放射治疗反应或保护正常组织,从而有助于提高治疗比率。